[Mezlocillin versus cefuroxime in urinary tract infections. A multicenter clinical study].
In a multicenter randomised clinical comparative study 96 urological patients with established urinary tract infection were treated in 50% with 2 g mezlocillin three times and in 50% with 1.5 g cefuroxime three times. Both antibiotics were shown to be antibacterially active substances with a high bacterial elimination rate. Three days after cessation of treatment the urine was sterile in 79 cases. Follow-up investigations 1-2 weeks later showed that the number of recurrences and reinfections was higher in the cefuroxime group than in the mezlocillin group. This difference is statistically significant so that mezlocillin can be considered the more effective antibiotic. Clinical and urine cytological results correlated with bacteriological results. Side effects were observed rarely, and toxic effects not at all.
D000328:Adult; D000368:Aged; D002444:Cefuroxime / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002511:Cephalosporins / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008802:Mezlocillin; D008875:Middle Aged; D010406:Penicillins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012008:Recurrence; D013997:Time Factors; D014552:Urinary Tract Infections / Q000188:drug therapy*
D002511:Cephalosporins; D010406:Penicillins; D002444:Cefuroxime; D008802:Mezlocillin
Mezlocillin versus Cefuroxim bei Harnwegsinfektionen. Klinische multizentrische Vergleichsstudie.